Assetmark, Inc Karuna Therapeutics, Inc. Transaction History

Assetmark, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$161.01 - $317.85 $187,415 - $369,977	1,164 Added 36.74%	4,332 $1.37 Million
Q3 2023 Oct 27, 2023	BUY	$164.66 - $218.08 $80,024 - $105,986	486 Added 18.12%	3,168 $535,000
Q2 2023 Aug 11, 2023	BUY	$176.32 - $240.22 $98,739 - $134,523	560 Added 26.39%	2,682 $581,000
Q1 2023 May 05, 2023	BUY	$161.33 - $204.36 $147,778 - $187,193	916 Added 75.95%	2,122 $385,000
Q4 2022 Feb 10, 2023	BUY	$191.53 - $236.82 $132,921 - $164,353	694 Added 135.55%	1,206 $236,000
Q3 2022 Nov 01, 2022	BUY	$123.79 - $277.42 $63,380 - $142,039	512 New	512 $115,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.